ESTRO 2025 - Abstract Book

S1093

Clinical – Head & neck

ESTRO 2025

Conclusion: The combined use of RT and CEMI in cHNSCC is feasible, demonstrating promising local control and OS and manageable toxicity in both groups. These preliminary findings support the integration of RT and CEMI into personalized treatment plans and highlight the need for prospective trials to refine sequencing and dosing strategies

Keywords: Cutaneous squamous cell cancer, Cemiplimab

References: 1 Di Lorenzo et al, 2024 https://doi.org/10.1007/s40487-023-00256-1 2 Kuzmanovszki et al, 2023 https://doi.org/10.3390/jcm12185966 3 Bailly-Caillé et al, 2023 R https://doi.org/10.3390/cancers15020495 4 Nardone et al, 2024 https://doi.org/10.1016/j.jaad.2024.06.023 5 Baggi et al, 2021 https://doi.org/10.1016/j.ejca.2021.08.018